Clinical trial · Observational
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
NCT06260410CI-TRIAL-00076329LUTRACrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood draw for ctDNA and circulating tumor cell collection. | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 44 months
- description
- Overall survival will be defined as the time from inclusion to death from any cause.
Secondary outcomes (5)
- measure
- Progression free survival
- timeFrame
- 44 months
- description
- Progression free survival will be defined as clinical, radiological or PSA progression according to Prostate Cancer Working Group 3 (PCWG3) or death, whichever occurs first.
- measure
- Heterogeneity of PSMA-positivity
- timeFrame
- 44 months
- description
- Exploring heterogeneity of PSMA-positivity in circulating tumor cells (CTC) prior to treatment with Lutetium-PSMA.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participants should be at least 18 years old. * Participants should be able to understand the written information and be able to provide informed consent. * Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care. Exclusion Criteria: None applicable
References
Publications (0)
Data not yet available
No reference posted for this study.